Optiscan Imaging (ASX:OIL) began its first in-human breast cancer clinical study at the Royal Melbourne Hospital to assess surgical margins in patients receiving treatment for breast cancer using its imaging devices, according to a Monday Australian bourse filing.

The 50-patient study will welcome patients for recruitment for in vivo clinical assessment of breast cancer margins following a lumpectomy procedure. It will use Optiscan's InVue precision surgery and InForm digital pathology imaging devices.

The study completed site initiation.

It will use the data for submissions to the US Food and Drug Administration.

The firm's shares jumped 10% on market close on Monday.